Allergan hikes profits forecast despite reform costs

Allergan (NYSE: AGN) reported better-than-expected first-quarter earnings on strong sales of its Botox anti-wrinkle drug; it slightly raised the low end of its 2010 profit forecast despite costs of U.S. healthcare reforms. Report

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.